China’s Jiuyuan Genetic Applies for Approval for Wegovy Biosimilar

China-based Jiuyuan Genetic has submitted a request seeking approval for a biosimilar version of Wegovy, a significant advancement in the pharmaceutical sector. The application for this biosimilar of Wegovy, a leading drug in the field, marks a pivotal moment for Jiuyuan Genetic in its progression in the industry. Financial implications of this new development are substantial, with Jiuyuan Genetic anticipating a transformative effect on its revenue streams. Experts anticipate positive reception for this biosimilar, emphasizing the increased accessibility it may provide to patients in need of Wegovy. The potential impact on the market is also a focal point of discussion,…